In the aging population, lower urinary tract (LUT) dysfunction is common and often leads to storage and voiding difficulties classified into overlapping symptom syndromes. Despite prevalence and consequences of these syndromes, LUT disorders continue to be undertreated simply because there are few therapeutic options. LUT function and structure were assessed in aged (>25 months) male and female Fischer 344 rats randomized to oral treatment with a purine nucleoside phosphorylase (PNPase inhibitor) 8-aminoguanine (8-AG) or vehicle for 6 weeks. The bladders of aged rats exhibited multiple abnormalities: tactile insensitivity, vascular remodeling, reduced collagen-fiber tortuosity, increased bladder stiffness, abnormal smooth muscle morphology, swelling of mitochondria, and increases in urodamaging purine metabolites. Treatment of aged rats with 8-AG restored all evaluated histological, ultrastructural, and physiological abnormalities toward that of a younger state. 8-AG is an effective treatment that ameliorates key age-related structural and physiologic bladder abnormalities. Because PNPase inhibition blocks metabolism of inosine to hypoxanthine and guanosine to guanine, likely uroprotective effects of 8-AG are mediated by increased bladder levels of uroprotective inosine and guanosine and reductions in urodamaging hypoxanthine and xanthine. These findings demonstrate that 8-AG has translational potential for treating age-associated LUT dysfunctions and resultant syndromes in humans.
Lori A. Birder, Amanda Wolf-Johnston, Alan J. Wein, Fangzhou Cheng, Mara Grove-Sullivan, Anthony J. Kanai, Alan M. Watson, Donna Stoltz, Simon C. Watkins, Anne M. Robertson, Diane Newman, Roger R. Dmochowski, Edwin K. Jackson
Title and authors | Publication | Year |
---|---|---|
8-Aminoguanine and Its Actions on Renal Excretory Function
Jackson EK, Gillespie DG, Mi Z |
2023 | |
Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice.
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Bakfer SD, Unadkat JD, Phelps MA, Govindarajan R |
Nature Communications | 2023 |
Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS.
Kanai AJ, Andersson KE, Birder LA, Fry CH |
2023 | |
Preventing mitochondrial reverse electron transport as a strategy for cardioprotection.
Prag HA, Murphy MP, Krieg T |
Basic Research in Cardiology | 2023 |
8-Aminopurines in the Cardiovascular and Renal Systems and Beyond
Jackson EK, Tofovic SP, Chen Y, Birder LA |
2023 | |
Binding asymmetry and conformational studies of the AtGSDA dimer
Jia Q, Zeng H, Li M, Tang J, Xiao N, Gao S, Li H, Zhang J, Zhang Z, Xie W |
Computational and Structural Biotechnology Journal | 2023 |
Aging and urinary control: Alterations in the brain-bladder axis.
Hardy CC, Korstanje R |
Aging Cell | 2023 |
Integrated omics analysis unveils a DNA damage response to neurogenic injury
Gheinani AH, Sack BS, Bigger-Allen A, Thaker H, Atta H, Lambrinos G, Costa K, Doyle C, Gharaee-Kermani M, Patalano S, Piper M, Cotellessa JF, Vitko D, Li H, Prabhakaran MK, Cristofaro V, Froehlich J, Lee RS, Yang W, Sullivan MP, Macoska JA, Adam RM |
2023 |